Helen Kathryn Reddel

Helen Kathryn Reddel

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Helen Kathryn Reddel

Woolcock Institute of Medical Research, Macquarie University, Sydney, Australia

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in The Lancet
Verified
Journal Article
Closed access
APAlberto Papi
Alberto Papi
CBChristopher Brightling
Christopher Brightling
SPSøren E Pedersen
Søren E Pedersen
HRHelen K Reddel
Helen K Reddel

1 July 2009 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
HRHelen K. Reddel
Helen K. Reddel
DTD. Robin Taylor
D. Robin Taylor
EBEric D. Bateman
Eric D. Bateman
LBLouis-Philippe Boulet
Louis-Philippe Boulet
HBHomer A. Boushey
Homer A. Boushey
SWSally E. Wenzel
Sally E. Wenzel
Background: The assessment of asthma control is pivotal to the evaluation of treatment response in individuals and in clinical trials. Previously, asthma control, severity, and exacerbations were defined and assessed in many different ways. Purpose: The Task Force was established to provide recommendations about standardization of outcomes relating to asthma control, severity, and exacerbations in clinical trials and clinical practice, for adults and children aged 6 years or older. Methods: A narrative literature review was conducted to evaluate the measurement properties and strengths/weaknesses of outcome measures relevant to asthma control and exacerbations. The review focused on diary variables, physiologic measurements, composite scores, biomarkers, quality of life questionnaires, and indirect measures. Results: The Task Force developed new definitions for asthma control, severity, and exacerbations, based on current treatment principles and clinical and research relevance. In view of current knowledge about the multiple domains of asthma and asthma control, no single outcome measure can adequately assess asthma control. Its assessment in clinical trials and in clinical practice should include components relevant to both of the goals of asthma treatment, namely achievement of best possible clinical control and reduction of future risk of adverse outcomes. Recommendations are provided for the assessment of asthma control in clinical trials and clinical practice, both at baseline and in the assessment of treatment response. Conclusions: The Task Force recommendations provide a basis for a multicomponent assessment of asthma by clinicians, researchers, and other relevant groups in the design, conduct, and evaluation of clinical trials, and in clinical practice.

23 July 2015 in European Respiratory Journal
Verified
Journal Article
Open access
HRHelen K. Reddel
Helen K. Reddel
EBEric D. Bateman
Eric D. Bateman
ABAllan Becker
Allan Becker
LBLouis-Philippe Boulet
Louis-Philippe Boulet
ACAlvaro A. Cruz
Alvaro A. Cruz
JFJ. Mark FitzGerald
J. Mark FitzGerald
Over the past 20 years, the Global Initiative for Asthma (GINA) has regularly published and annually updated a global strategy for asthma management and prevention that has formed the basis for many national guidelines. However, uptake of existing guidelines is poor. A major revision of the GINA report was published in 2014, and updated in 2015, reflecting an evolving understanding of heterogeneous airways disease, a broader evidence base, increasing interest in targeted treatment, and evidence about effective implementation approaches. During development of the report, the clinical utility of recommendations and strategies for their practical implementation were considered in parallel with the scientific evidence.This article provides a summary of key changes in the GINA report, and their rationale. The changes include a revised asthma definition; tools for assessing symptom control and risk factors for adverse outcomes; expanded indications for inhaled corticosteroid therapy; a framework for targeted treatment based on phenotype, modifiable risk factors, patient preference, and practical issues; optimisation of medication effectiveness by addressing inhaler technique and adherence; revised recommendations about written asthma action plans; diagnosis and initial treatment of the asthma−chronic obstructive pulmonary disease overlap syndrome; diagnosis in wheezing pre-school children; and updated strategies for adaptation and implementation of GINA recommendations.

17 May 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
POPaul M. O’bYrne
Paul M. O’bYrne
JFJ. Mark FitzGerald
J. Mark FitzGerald
EBEric D. Bateman
Eric D. Bateman
PBPeter Barnes
Peter Barnes
NZNanshan Zhong
Nanshan Zhong
HRHelen K. Reddel
Helen K. Reddel
In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β2-agonist may be an alternative to conventional treatment strategies.

1 January 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
HRHelen K. Reddel
Helen K. Reddel
LBLeonard B. Bacharier
Leonard B. Bacharier
EBEric D. Bateman
Eric D. Bateman
CBChristopher E. Brightling
Christopher E. Brightling
GBGuy G. Brusselle
Guy G. Brusselle
LBLouis-Philippe Boulet
Louis-Philippe Boulet
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting β2-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS–formoterol reduces severe exacerbations by ⩾60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS–formoterol as the reliever at all steps: as needed only in Steps 1–2 (mild asthma), and with daily maintenance ICS–formoterol (maintenance-and-reliever therapy, “MART”) in Steps 3–5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS–long-acting β2-agonist (Steps 3–5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6–11 years, new treatment options are added at Steps 3–4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.

19 October 2021 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
HRHelen K. Reddel
Helen K. Reddel
LBLeonard B. Bacharier
Leonard B. Bacharier
EBEric D. Bateman
Eric D. Bateman
CBChristopher E. Brightling
Christopher E. Brightling
GBGuy G. Brusselle
Guy G. Brusselle
LBLouis-Philippe Boulet
Louis-Philippe Boulet
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta2-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as- needed combination ICS-formoterol reduces severe exacerbations by >60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as-needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta2-agonist (LABA) (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age-groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment and review remain essential to optimize asthma outcomes.